MYND Lifesciencs Inc
MYND Life Sciences Inc., a life sciences-based neuro-pharmaceutical drug development company, advances medicines based on neuro-anti-inflammatory substances for depressive disorders through science and clinical trials in Canada and the United States. It focuses on the analysis of psilocin and psilocybin extracts, and analogs. MYND Life Sciences Inc. is based in Port Coquitlam, Canada.
MYND Lifesciencs Inc (MYNDF) - Net Assets
Latest net assets as of July 2024: $-5.99 Million USD
Based on the latest financial reports, MYND Lifesciencs Inc (MYNDF) has net assets worth $-5.99 Million USD as of July 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($719.72K) and total liabilities ($6.71 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-5.99 Million |
| % of Total Assets | -832.1% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
MYND Lifesciencs Inc - Net Assets Trend (2021–2023)
This chart illustrates how MYND Lifesciencs Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MYND Lifesciencs Inc (2021–2023)
The table below shows the annual net assets of MYND Lifesciencs Inc from 2021 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-10-31 | $-4.98 Million | -40.91% |
| 2022-10-31 | $-3.53 Million | -5096.83% |
| 2021-10-31 | $-67.97K | -- |
Equity Component Analysis
This analysis shows how different components contribute to MYND Lifesciencs Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 508518200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (October 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $4.53 Million | % |
| Total Equity | $-4.98 Million | 100.00% |
MYND Lifesciencs Inc Competitors by Market Cap
The table below lists competitors of MYND Lifesciencs Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fridenson
TA:FRDN
|
$332.49K |
|
Grade Upon Technology Corp
TWO:6739
|
$332.58K |
|
Procaps Group S.A. Warrants
NASDAQ:PROCW
|
$332.72K |
|
PILGRIMS PRIDE
BE:6PP
|
$332.72K |
|
CARETRUST REIT DL-01
F:7XC
|
$332.25K |
|
Avio SpA
STU:2ZP
|
$332.09K |
|
MICRONIC MYDATA
BE:MLT
|
$331.84K |
|
WEIR GROUP - Dusseldorf Stock Exchang
DU:42W
|
$331.55K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MYND Lifesciencs Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -3,532,179 to -4,977,161, a change of -1,444,982.
- Net loss of 1,517,860 reduced equity.
- Other factors increased equity by 72,878.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.52 Million | -30.5% |
| Other Changes | $72.88K | +1.46% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares MYND Lifesciencs Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-10-31 | $0.00 | $0.01 | x |
| 2022-10-31 | $-0.08 | $0.01 | x |
| 2023-10-31 | $-0.10 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MYND Lifesciencs Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.36 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.21 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.02 Million |
Industry Comparison
This section compares MYND Lifesciencs Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MYND Lifesciencs Inc (MYNDF) | $-5.99 Million | 0.00% | N/A | $332.44K |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |